New combo therapy targets tough lung cancer
Disease control
Ongoing
This study tests a new drug called EIK1001 combined with standard treatments (pembrolizumab and chemotherapy) in 70 people with stage 4 non-small cell lung cancer who haven't had prior treatment. The main goal is to check safety and side effects, while also seeing how well the tu…
Phase: PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC